



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached (33 pages) (Use several sheets if necessary)	ATTY. DOCKET NO.: STRM 8432W1	SERIAL NO.: 10/511,818 U.S. National Phase International Appln. N PCT/US03/12602
	APPLICANT: Meir Strahilevitz	
	Filing Date: July 7, 2004 Group: 1644	

U.S. PATENT DOCUMENTS


Examiner Initial	Document Number	Kind Code (click here)	Patent Issue Date OR US App. Pub. Date OR US Non-Published Application Filing Date	Name
BS	US 5 1 6 0 4 8 3		Nov. 3, 1992	Postlethwaite et al
	US			
	US			
	US			
	US			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Translation
				Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BS ↓		Dalum I et al, Therapeutic Antibodies Elicited by Immunization Against TNF-ALPHA, Nature Biotechnology, Nature Publishing, US, Vol. 17, no. 7, 1999, pp.666-669
		Nagahira K et al, Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha), Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 222, no. 1-2, 1999, pp. 83-92
		Ten hagen T L M et al; A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor- 'alpha' And cytotoxic agents", Advanced Drug Delivery Reviews 1997, Netherlands, Vol. 24, no. 2-3, pp. 245-256

EXAMINER 	DATE CONSIDERED 10/1/07
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)